Astrotech Corporation — Form 10-K Summary
Period: Fiscal year ended June 30, 2017, with comparison to fiscal 2016. The request metadata says “2015 Q4,” but the filing is for FY2017.
Business context
Astrotech develops and commercializes technology through Astro Scientific, which includes 1st Detect (chemical analyzers) and Astrogenetix (microgravity-based vaccine research), and Astral Images (AI-enabled film digitization and enhancement). In FY2017, substantially all revenue came from government-related subcontract work. Astrotech acquired the remaining minority interest in Astral, bringing its ownership to 100%.
Financial performance
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $2.328 million | $2.671 million |
| Gross profit / margin | $1.035 million / 44% | $0.339 million / 13% |
| Operating expenses | $13.095 million | $14.177 million |
| Net loss attributable to Astrotech | $11.582 million | $13.095 million |
| Loss per share | $0.57 | $0.64 |
| Cash used in operating activities | $8.821 million | $13.324 million |
Revenue fell 13%, mainly because FY2016 included $0.2 million of space-grade handrail sales that did not recur. Gross margin improved as production issues were lower than anticipated. Lower operating expenses reflected reduced staffing and other cost savings. Astro Scientific recorded $2.320 million of revenue and a $9.058 million pretax loss; Astral recorded $8,000 of revenue and a $2.696 million pretax loss.
Financial position and liquidity
- At June 30, 2017, cash and cash equivalents were $2.184 million, short-term investments $10.900 million, and long-term investments $1.990 million. Management cited $13.1 million of cash and short-term investments and approximately $11.9 million of net working capital.
- Total assets were $18.835 million, down from $30.523 million; stockholders’ equity was $16.770 million, down from $28.627 million. Current liabilities were $1.809 million.
- The company had no outstanding debt or credit facilities. Investing activities provided $7.881 million, largely from investment sales and maturities; financing activities used $1.275 million, primarily for share repurchases.
- Management said existing cash and cash equivalents were sufficient for expected liquidity requirements for the coming year. Operating cash burn and continued investment needs remain important considerations.
Developments, outlook, and risks
- Management engaged Chardan Capital Markets to advise on strategic alternatives for 1st Detect, potentially including partnerships, licensing, acquisitions, or a sale; no outcome was assured.
- 1st Detect reported positive preliminary pre-clinical results for its BreathDetect 1000 with UT Health San Antonio. The product remains under development and is not an established commercial revenue source.
- The first phase of the military NGCD program was completed, but partner Battelle indicated it would not pursue the next phase. Astrotech was evaluating options to remain in the competition. The next phase of the TSA program was also not guaranteed.
- Revenue was highly concentrated: two customers accounted for all FY2017 revenue, and one partner represented all accounts receivable at year-end.
- On August 24, 2017, Nasdaq notified the company that its share price had failed the $1.00 minimum bid requirement. Astrotech had until February 20, 2018 to regain compliance or could face delisting. The September 15, 2017 closing price was $0.88.
- Other risks include the need to raise or preserve capital, uncertain government funding and contract timing, product acceptance and technical milestones, competition, and the timing of 4K/HDR film-conversion demand. The company reported no material pending legal proceedings and no impairments in FY2017 or FY2016.
Most important facts for investors to verify
- Whether the reported cash runway supports the company’s expected operating and development needs, given $8.821 million of FY2017 operating cash use.
- Any developments in 1st Detect’s strategic-alternatives process and the status of TSA and NGCD opportunities.
- Whether BreathDetect advances beyond preliminary pre-clinical work and whether Astral generates material commercial revenue.
- Customer concentration, contract renewals, and receivable collections.
- Nasdaq bid-price compliance and any financing, share issuance, or other actions affecting liquidity and dilution.